Pfizer announced today the successful conclusion of their mRNA-based BNT162b2 vaccine for SARS-CoV-2 produced in partnership with BioNTech. This news comes shortly after...
China's "high risk" professionals have been vaccinated with experimental COVID-19 vaccines since July. The Chinese National Health Commission revealed earlier this week these professionals include medical professionals working on the front lines and border officials.
The agreement will expand funding by up to $472 million in part to support the Phase 3 study of mRNA-1273, the company's COVID-19 vaccine. This funding expands on Moderna's previous agreement with BARDA for $483 million.
According to a press release today and keeping to the timeline set last week, Clinical researchers are this week set to begin human trials of a new coronavirus vaccine developed by researchers at Imperial College London.
Sinovac today announced the signing of a clinical development collaboration agreement to advance the clinical trials of CoronaVac, Sinovac’s inactivated vaccine candidate against COVID-19 to Phase III.
In a report from the Associated French Press, Pfizer head Albert Bourla claimed a vaccine may come as early as the end of October, acknowledging the date requires an ideal path.
Russia is claiming to be the first to bring to market a effective, direct-acting antiviral drug to treat symptoms of COVID-19.
The aggressive timeline of Project Warpspeed is confounding to the scientific community at large. Dr, Karen Patel was a senior medical official in the Obama administration and was a key member of the H1N1 virus...